MicroRNA‐34a in coronary heart disease: Correlation with disease risk, blood lipid, stenosis degree, inflammatory cytokines, and cell adhesion molecules

MicroRNA‐34a (miR‐34a) plays an essential role in regulating blood lipid, inflammation, cell adhesion molecules, and atherosclerosis, the latter factors are closely involved in the etiology of coronary heart disease (CHD). However, the clinical value of miR‐34a in CHD patients' management is rarely reported. Hence, this study aimed to assess the correlation of miR‐34a with disease risk, blood lipid, coronary artery stenosis, inflammatory cytokines, and cell adhesion molecules of CHD.

• Publication year

  2021

• Venue

  Journal of clinical laboratory analysis (Print)

• Publication date

  2021-12-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jcla.24138PMID 34861059PMCID 8761464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhanced Expression of miR-34a Enhances Escherichia coli Lipopolysaccharide-Mediated Endometritis by Targeting LGR4 to Activate the NF-κB Pathway

  2021cited by this paper
• MicroRNA‐34a in coronary heart disease: Correlation with disease risk, blood lipid, stenosis degree, inflammatory cytokines, and cell adhesion molecules

  2021cited by this paper
• Additive contribution of microRNA-34a/b/c to human arterial ageing and atherosclerosis.

  2021cited by this paper
• Prevalence of dyslipidemia and associated risk factors among adult residents of Shenmu City, China

  2021cited by this paper
• Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.

  2021cited by this paper
• Indoxyl sulfate promotes the atherosclerosis through up-regulating the miR-34a expression in endothelial cells and vascular smooth muscle cells in vitro.

  2020cited by this paper
• Association of Exosomal miR-34a with Markers of Dyslipidemia and Endothelial Dysfunction in Children and Adolescents with T1DM

  2020cited by this paper
• Macrophage miR-34a Is a Key Regulator of Cholesterol Efflux and Atherosclerosis.

  2020cited by this paper
• Circular RNA MGAT1 regulates cell proliferation and apoptosis in hypoxia-induced cardiomyocytes through miR-34a/YAP1 axis.

  2020cited by this paper
• miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload.

  2020cited by this paper
• The Interplay between Oxidative Stress and miRNAs in Obesity-Associated Hepatic and Vascular Complications

  2020cited by this paper
• Metabolomics and its application in the treatment of coronary heart disease with traditional Chinese medicine.

  2019cited by this paper
• Inhibition of P53/miR‐34a improves diabetic endothelial dysfunction via activation of SIRT1

  2019cited by this paper
• Adipocyte-secreted exosomal microRNA-34a inhibits M2 macrophage polarization to promote obesity-induced adipose inflammation

  2019cited by this paper
• Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease.

  2019influential reference
• Expression of miR-34a in basal cell carcinoma patients and its relationship with prognosis.

  2019cited by this paper
• NF-κB-driven miR-34a impairs Treg/Th17 balance via targeting Foxp3.

  2019cited by this paper
• Inflammatory biomarkers of coronary heart disease.

  2018cited by this paper
• Downregulation of miR-34a promotes endothelial cell growth and suppresses apoptosis in atherosclerosis by regulating Bcl-2

  2018cited by this paper
• Circulating soluble adhesion molecules ICAM 1 and VCAM 1 and incident coronary heart disease the PRIME Study

  2018cited by this paper
• Inhibition of miR‑34a prevents endothelial cell apoptosis by directly targeting HDAC1 in the setting of atherosclerosis.

  2018cited by this paper
• ATGL Promotes Autophagy/Lipophagy via SIRT1 to Control Hepatic Lipid Droplet Catabolism.

  2017cited by this paper
• Inflammatory biomarkers of coronary heart disease.

  2017cited by this paper
• MicroRNA-34a and Impaired FGF19/21 Signaling in Obesity.

  2016cited by this paper
• Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies

  2016cited by this paper
• MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort

  2015cited by this paper
• A Metabolic Stress-inducible miR-34a-HNF4α Pathway Regulates Lipid and Lipoprotein Metabolism

  2015cited by this paper
• Acute Coronary Syndrome

  2015influential reference
• miRNA-34a reduces neointima formation through inhibiting smooth muscle cell proliferation and migration.

  2015cited by this paper
• Shear-sensitive microRNA-34a modulates flow-dependent regulation of endothelial inflammation

  2015cited by this paper
• Differential Inflammatory MicroRNA and Cytokine Expression in Pulmonary Sarcoidosis

  2014cited by this paper
• Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders.

  2013cited by this paper
• 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study.

  2011cited by this paper
• 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2011cited by this paper
• NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin

  2010cited by this paper
• Atherosclerotic coronary heart disease-epidemiology, classification and management.

  2010cited by this paper
• Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease.

  2008cited by this paper
• Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study.

  2003cited by this paper
• Inflammatory markers and coronary heart disease.

  2002cited by this paper
• Hypertension and coronary heart disease

  2002cited by this paper
• Inflammatory markers and coronary heart disease

  2002cited by this paper
• Diabetes mellitus and coronary heart disease.

  1998cited by this paper
• Coronary heart disease: overview.

  1996cited by this paper
• A more meaningful scoring system for determining the severity of coronary heart disease.

  1983cited by this paper
• Oncotargets and Therapy Dovepress Dovepress the Predictive Effect of Overexpressed Mir-34a on Good Survival of Cancer Patients: a Systematic Review and Meta-analysis

  year unknowncited by this paper

• Expression of Serum and Exosomal microRNA-34a in Subjects with Increased Fat Mass

  2025cites this paper
• The Role of MicroRNAs in the Pathophysiology and Management of Heart Failure: From Molecular Mechanisms to Clinical Application

  2025cites this paper
• Correlation between α-ketoglutarate and the oxidative stress response in patients with coronary heart disease and prognostic analysis of interventional therapy for coronary heart disease

  2025cites this paper
• Depression and coronary heart disease: mechanisms, interventions, and treatments

  2024cites this paper
• Identification of the susceptible genes and mechanism underlying the comorbid presence of coronary artery disease and rheumatoid arthritis: a network modularization analysis

  2023cites this paper
• MicroRNA-34a in cardiovascular disease: a glimpse into the future

  2023cites this paper
• Serum‑derived exosomal hsa‑let‑7b‑5p as a biomarker for predicting the severity of coronary stenosis in patients with coronary heart disease and hyperglycemia

  2023cites this paper
• MicroRNA-specific therapeutic targets and biomarkers of apoptosis following myocardial ischemia–reperfusion injury

  2023cites this paper
• A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research

  2022cites this paper
• The Functionality of Apigenin as a Novel Cardioprotective Nutraceutical with Emphasize on Regulating Cardiac Micro RNAs:.

  2022cites this paper
• MicroRNAs as Biomarkers for Coronary Artery Disease Related to Type 2 Diabetes Mellitus—From Pathogenesis to Potential Clinical Application

  2022influential citation
• Clinical Application of Serum microRNAs in Atherosclerotic Coronary Artery Disease

  2022cites this paper
• MicroRNA‐34a in coronary heart disease: Correlation with disease risk, blood lipid, stenosis degree, inflammatory cytokines, and cell adhesion molecules

  2021cites this paper